Prospective Grant of Exclusive License: Use of 3-deazaneplanocin A and Cyclopentenyl Cytosine for the Development of the Topical Treatment of Basal Cell Carcinoma and Resistant Herpes Simplex Virus Infections, 6026 [05-2126]
Download as PDF
<![CDATA[
6026
Federal Register / Vol. 70, No. 23 / Friday, February 4, 2005 / Notices
Date: March 15, 2005.
Time: 8 a.m. to 4 p.m.
Agenda: Healthcare Information
Technology Standards.
Place: Hubert H. Humphrey Building,
Room 800, 200 Independence Avenue,
Washington, DC 20201.
Contact Person: Ms. Dana Haza, Director,
Commission on Systemic Interoperability,
National Library of Medicine, National
Institutes of Health, Building 38, Room 2N21,
Bethesda, MD 20894. (301) 594–7520.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The comments should include
the name, address, telephone number and,
when applicable, the business or professional
affiliation of the interested person.
In the interest of security, HHS has
procedures for entrance into the building by
non-government employees. Persons without
a government I.D. will need to show a photo
I.D. at the security desk upon entering the
building.
Dated: January 28, 2005.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–2130 Filed 2–3–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of 3-deazaneplanocin A
and Cyclopentenyl Cytosine for the
Development of the Topical Treatment
of Basal Cell Carcinoma and Resistant
Herpes Simplex Virus Infections
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of a an
exclusive license to practice the
invention embodied in:
(1) U.S. Patent No. 4,968,690, issued
Nov. 6, 1990, entitled ‘‘3DEAZANEPLANOCIN A AND METHOD
OF PREPARATION’’ (E–493–1985/0–
US–02) (Inventors: Victor E. Marquez,
John S. Driscoll, Mu–III Lim,
Christopher K Tseng, Alberto Haces and
Robert Glazer) (NCI), a continuation of
prior application 867,583, filed May 27,
1986, now abandoned.
(2) U.S. Patent No. 4,975,434, issued
Dec. 4, 1990, entitled ‘‘ANTIVIRAL
AND ANTICANCER CYCLOPENTENYL
CYTOSINE’’ (E–493–1985/1–US–01)
(Inventors: Victor E. Marquez, John S.
VerDate jul<14>2003
18:52 Feb 03, 2005
Jkt 205001
Driscoll, Mu–III Lim, Christopher K
Tseng, Alberto Haces and Robert Glazer)
(NCI), a continuation of prior
application 867,583, filed May 27, 1986,
now abandoned to GRX
Pharmaceuticals (hereafter GRX), having
a place of business in Marlboro, New
Jersey. The patent rights in these
inventions have been assigned to the
United States of America.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before April
5, 2005, will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Sally Hu, Ph.D., M.B.A., Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804; email: hus@od.nih.gov; telephone: (301)
435–5606; Facsimile: (301) 402–0220.
SUPPLEMENTARY INFORMATION: The
technology described in E–493–1985/0–
US–02 relates to antiviral and cancer
chemotherapy and, more particularly, to
the compound 3-deazaneplanocin A and
related compounds and a method of
preparation thereof, as well as the
methods of preparation of a great variety
of unsaturated (cyclopentenyl)
carbocyclic nucleosides.
The technology described in E–493–
1985/1–US–01 relates to antiviral and
cancer chemotherapy and, more
particularly, to cyclopentenyl
pyrimidines which can be used for
antiviral and cancer chemotherapy, as
well as to methods of preparation of
these compounds.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
The field of use may be limited to the
development of the topical treatment of
basal cell carcinoma and resistant
herpes simplex virus infections.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Dated: January 21, 2005.
Mark L. Rohrbaugh,
Director, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–2126 Filed 2–3–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Construction and Operation of the
National Biodefense Analysis and
Countermeasures Center (NBACC)
Facility by the Department of
Homeland Security at Fort Detrick,
Maryland: Record of Decision
Science and Technology
Directorate, Department of Homeland
Security.
AGENCY:
ACTION:
Notice.
SUMMARY: In keeping with the purposes
of the National Environmental Policy
Act (NEPA), the Department of
Homeland Security (DHS), in
cooperation with the United States
Army Garrison, Fort Detrick, decided on
January 26, 2005, after completion of the
Final Environmental Impact Statement
(FEIS) and a thorough consideration of
public comments, to implement the
Preferred Alternative in the FEIS. This
action involves the construction and
operation of the National Biodefense
Analysis and Countermeasures Center
Facility by DHS on a site adjacent to
existing U.S. Army Medical Research
Institute of Infectious Diseases facilities
at Fort Detrick, Maryland. The notice of
availability of the Draft Environmental
Impact Statement is at 69 FR 56075 and
the notice of intent to prepare an
Environmental Impact Statement is at
69 FR 31830.
Copies of the Final EIS and
this Record of Decision may be obtained
by calling or mailing a request to: Dr.
Kevin Anderson, Department of
Homeland Security, 7435 New
Technology Way, Suite A, Frederick,
Maryland, 21703, by telephone (301)
846–2156, fax (301) 682–3662 or e-mail
kevin.anderson@dhs.gov. The Final EIS
and this Record of Decision are
available at https://
www.detrick.army.mil/.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Questions regarding the Final EIS or this
Record of Decision can be submitted by
calling or mailing them to Dr. Kevin
Anderson at the above phone number or
address.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 70, Number 23 (Friday, February 4, 2005)]
[Notices]
[Page 6026]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-2126]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of 3-deazaneplanocin
A and Cyclopentenyl Cytosine for the Development of the Topical
Treatment of Basal Cell Carcinoma and Resistant Herpes Simplex Virus
Infections
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
a an exclusive license to practice the invention embodied in:
(1) U.S. Patent No. 4,968,690, issued Nov. 6, 1990, entitled ``3-
DEAZANEPLANOCIN A AND METHOD OF PREPARATION'' (E-493-1985/0-US-02)
(Inventors: Victor E. Marquez, John S. Driscoll, Mu-III Lim,
Christopher K Tseng, Alberto Haces and Robert Glazer) (NCI), a
continuation of prior application 867,583, filed May 27, 1986, now
abandoned.
(2) U.S. Patent No. 4,975,434, issued Dec. 4, 1990, entitled
``ANTIVIRAL AND ANTICANCER CYCLOPENTENYL CYTOSINE'' (E-493-1985/1-US-
01) (Inventors: Victor E. Marquez, John S. Driscoll, Mu-III Lim,
Christopher K Tseng, Alberto Haces and Robert Glazer) (NCI), a
continuation of prior application 867,583, filed May 27, 1986, now
abandoned to GRX Pharmaceuticals (hereafter GRX), having a place of
business in Marlboro, New Jersey. The patent rights in these inventions
have been assigned to the United States of America.
DATES: Only written comments and/or application for a license, which
are received by the NIH Office of Technology Transfer on or before
April 5, 2005, will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Sally Hu, Ph.D., M.B.A., Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804; e-mail: hus@od.nih.gov; telephone:
(301) 435-5606; Facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: The technology described in E-493-1985/0-US-
02 relates to antiviral and cancer chemotherapy and, more particularly,
to the compound 3-deazaneplanocin A and related compounds and a method
of preparation thereof, as well as the methods of preparation of a
great variety of unsaturated (cyclopentenyl) carbocyclic nucleosides.
The technology described in E-493-1985/1-US-01 relates to antiviral
and cancer chemotherapy and, more particularly, to cyclopentenyl
pyrimidines which can be used for antiviral and cancer chemotherapy, as
well as to methods of preparation of these compounds.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The field of use may be limited to the development of the topical
treatment of basal cell carcinoma and resistant herpes simplex virus
infections.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: January 21, 2005.
Mark L. Rohrbaugh,
Director, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 05-2126 Filed 2-3-05; 8:45 am]
BILLING CODE 4140-01-P
